Regardless of PD-L1 expression levels, neoadjuvant Opdivo with chemotherapy showed a greater reduction in the risk of disease recurrence, progression or death than chemotherapy alone
Exploratory analyses from the Phase 3 CheckMate -816 trial will be shared in a late-breaking oral presentation at the European Society for Medical Oncology Congress 2023
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced three-year follow-up results from exploratory analyses of the Phase 3 CheckMate -816 trial, demonstrating sustained event-free survival (EFS) and promising overall survival (OS) trends with three cycles of Opdivo (nivolumab) in combination with platinum-based chemotherapy for the neoadjuvant treatment of patients with resectable non-small cell lung cancer (NSCLC), regardless of PD-L1 expression levels. Neoadjuvant Opdivo with chemotherapy also showed improvements in pathologic complete response (pCR) and major pathologic response (MPR) over chemotherapy alone in PD-L1 ≥1% and